By Jacob Gronholt-Pedersen

COPENHAGEN (Reuters) -Novo Nordisk said on Thursday its experimental obesity drug CagriSema significantly reduced blood pressure in a late-stage trial, as the Danish drugmaker seeks to demonstrate health benefits beyond weight loss for a treatment that has disappointed investors.

Novo had positioned CagriSema as a more potent successor to its blockbuster Wegovy, but lower-than-expected weight loss data published in December wiped $125 billion from its market value. The underwhelming results prompted Novo to launch a new late-stage trial in June.

The drug combines cagrilintide, which mimics the pancreatic hormone amylin, and semaglutide, the active ingredient in Wegovy.

CagriSema reduced systolic blood pressure by 10.9 mmHg over 68 weeks, compared with 8.8 mmH

See Full Page